28 Feb

How AstraZeneca Performed in 4Q17 and Fiscal 2017

WRITTEN BY Daniel Collins

Astra Zeneca revenue trends

In 4Q17, AstraZeneca (AZN) reported revenues of $5.8 billion, which reflected ~3.0% growth on a year-over-year (or YoY) basis and an ~7.0% decline on a quarter-over-quarter basis. In 4Q17, AstraZeneca generated revenues of $5.5 billion from product sales and $290.0 million in externalization revenues.

In fiscal 2017, AstraZeneca reported revenues of $22.5 billion, which is an ~2.0% YoY decline. In 2017, AstraZeneca reported revenues of ~$20.2 billion from product sales while its externalization revenues totaled $2.3 billion. In 2017, AstraZeneca’s externalization revenues witnessed 37.0% YoY growth.

 

How AstraZeneca Performed in 4Q17 and Fiscal 2017

In 2017, AstraZeneca’s CVMD (cardiovascular and metabolic disease) drugs Brilinta and Farxiga witnessed 29.0% and 28.0% YoY growth, respectively. AstraZeneca’s major oncology drugs witnessed steady growth, which pushed the company’s product sales.

In 4Q17, AstraZeneca reported its core operating profit and core earnings per share (or EPS) of $1.7 billion and $1.30, respectively, which reflected ~12.0% decline and 7.0% growth on a YoY basis.

In fiscal 2017, AstraZeneca reported a core operating profit and EPS of $6.86 billion and $4.28, respectively, which is ~2.0% growth and 1.0% decline on a YoY basis.

Regional revenue trends

In 4Q17, in the US and Europe markets, AstraZeneca generated revenues of $1.8 billion and $1.3 billion, respectively, which reflected ~9.0% growth and 3.0% decline on a YoY basis.

In 4Q17, in the emerging markets, AstraZeneca generated revenues of $1.6 billion for ~10.0% growth on a YoY basis. In 4Q17, in China, AstraZeneca reported revenues of $813.0 million and revenues of $817.0 million in emerging markets such as Brazil, India, Mexico, Russia, and Turkey.

In 4Q17, in Japan, AstraZeneca generated revenues of $563.0 million which is ~10.0% growth on a YoY basis.

In the US, Europe, China, and Japan, AstraZeneca reported 2017 revenues of $6.2 billion, $4.8 billion, $3.0 billion, and $2.2 billion, respectively. These revenues reflected respective YoY growth of ~31.0%, ~24.0%, ~15.0%, and ~11.0%.

Expense trends

In fiscal 2017, AstraZeneca reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $5.8 billion and $10.2 billion, respectively, which reflected an ~2.0% decline and 9.0% growth on a YoY basis.

In 2017, AstraZeneca’s peers in the biopharmaceuticals market Eli Lilly (LLY), Bristol-Myers Squibb (BMY), and Amgen (AMGN) reported revenues of $6.1 billion, $5.4 billion, and $5.8 billion, respectively.

Latest articles

After opening on a bearish note on Wednesday, Tesla (TSLA) was trading with 4.8% losses for the day, near $195.25 at 1:16 PM ET.

With voting conducted in seven phases panning six weeks, India’s (EPI) elections have been a grand affair—to say the least. Tomorrow is the day of the results.

Qualcomm (QCOM) stock fell more than 10% in the first half of trading on May 22 after it lost its licensing lawsuit with the US FTC (Federal Trade Commission).

Apple (AAPL) suffered a setback recently when the US Supreme Court allowed an antitrust lawsuit against the company to proceed.

Today doesn’t seem to be a good day for electric vehicle companies. Earlier today, NIO stock hit an all-time low of $4.00.

22 May

Cannabis Stocks Struggle to Find Direction

WRITTEN BY Adam Jones

The cannabis sector has been struggling to find direction on May 22, with cannabis stocks trading on a largely mixed note in the first half.

172.31.38.64